Cancer research

GSK teams with King’s College to use AI to fight cancer

Artificial intelligence will be used to develop personalised treatments while investigating role of genetics The pharmaceuticals firm GSK has struck a five-year partnership with King’s College London to use artificial intelligence to develop personalised treatments for cancer by investigating the role played by genetics in the disease. The tie-up, which involves 10 of the drug …

GSK teams with King’s College to use AI to fight cancer Read More »

Cancer research faces uncertain post-COVID landscape

There’s a bright future ahead for cancer research in the UK, but only if the government is able to implement a clear plan for funding and development going forward, says The Institute of Cancer Research, London’s Paul Workman. Cancer research in the UK risks facing a “perfect storm” of stalled work and reduced funding that …

Cancer research faces uncertain post-COVID landscape Read More »

Cancer Centers Rebounding From COVID-19 Can Grow By Making the Most of New Technologies for Clinical Trials

For community cancer centers that rely on patient reimbursement to stay afloat, a smart data-driven approach to clinical trials provides a foundation for future growth. Brenda Noggy Dr. Tandy Tipps By TANDY TIPPS and BRENDA NOGGY Covid-19’s tragic, devastating impact on cancer treatment is now well documented. Cancer screenings dropped by almost 90 percent at …

Cancer Centers Rebounding From COVID-19 Can Grow By Making the Most of New Technologies for Clinical Trials Read More »

The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy

Likewise, it was demonstrated by actualizing high throughput screening in-vitro framework that the drug fenbendazole is successful, not just against standard non-small cell lung cancer, NSCLC, yet in addition against the KRAS-mutant malignancy which seems, by all accounts, aggressive, barely accessible by chemotherapy and very normal (thirty percent of total cases of NSCLS) in people. …

The drug Fenbendazole can make tumors sensitive to radiotherapy just like agents of chemotherapy Read More »

BioNTech’s Covid vaccine is a triumph of innovation and immigration | Hans-Werner Sinn

Pioneered by a Turkish-German couple, its significance exceeds its practical value The world took note when the German startup BioNTech announced its breakthrough in the development of a new type of vaccine to combat Covid-19. After testing tens of thousands of people, BioNTech’s vaccine has been shown to be 95% effective in providing protection for …

BioNTech’s Covid vaccine is a triumph of innovation and immigration | Hans-Werner Sinn Read More »

Complimentary trend analysis report: Emerging trends in pancreatic cancer research

Pancreatic cancer sadly remains one of the most deadly cancers in existence, partly because it often goes undiagnosed until it has already metastasized. Finding new and better therapies to fight pancreatic cancer means accelerating the research. A new report just released from Elsevier’s Professional Services Group, titled Text mining to identify emerging trends in the …

Complimentary trend analysis report: Emerging trends in pancreatic cancer research Read More »

Made-in-Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials

First dose of ETC-159 administered in Phase 1B of clinical trials, advancing the development of this drug to treat solid tumours Made-in-Singapore cancer drug, ETC-159, has achieved a new developmental milestone in achieving “First Patient First Visit[1]” in Phase 1B. The first dose of ETC-159 has been administered to patients in this new phase of …

Made-in-Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials Read More »

AstraZeneca signs deal worth up to £4.7bn for cancer treatment

Pharmaceuticals company buys global rights to new technology from Japan’s Daiichi Sankyo Drugmaker AstraZeneca could pay up to $6bn (£4.7bn) for the global rights to a new Japanese cancer treatment. The Anglo-Swedish pharmaceutical company said it would pay $1bn (£800m) up front to its partner Daiichi Sankyo. Related: Covid-19 is Big Pharma’s chance to impress. …

AstraZeneca signs deal worth up to £4.7bn for cancer treatment Read More »